Prognostic value of head-up tilt test with intravenous beta-blocker administration in assessing the efficacy of therapy in patients with vasovagal syncope.
BACKGROUND
Although beta-blockers are frequently used in order to prevent the recurrence of vasovagal syncope, the efficacy of this treatment is difficult to determine.


OBJECTIVE
To determine if the result of a tilt test with an intravenously administered beta-blocker can predict the long-term efficacy of beta-blockade.


METHODS
The study group consisted of 62 patients (29 females, mean age 32.8 +/- 12.3 years and 33 males, mean age 35.9 +/- 18.2 years) with at least two syncopal episodes during 6 months preceding the positive tilt test. After the baseline tilt test, propranolol (0.1 mg/kg BW) was administered intravenously and the tilt test was repeated. Beta-blockade was considered effective if the subsequent tilt test proved negative (complete efficacy) or if the time until the occurrence of syncope at the subsequent tilt test was longer compared to the baseline test (partial efficacy). All the patients were put on continuous propranolol treatment and were followed up for a period of 1 year or until the time when syncope recurred.


RESULTS
Intravenously administered propranolol prevented (n = 33) or delayed (n = 18) the occurrence of syncope at the tilt test in 51 patients (82%), while it was found ineffective in the remaining 11 patients (18%). During the 8.6 +/- 6.7 months (range 1-14) of the follow-up period, the syncope recurred in 20 patients (32%), with 13 patients (25%) in the group where intravenously administered propranolol proved effective versus 7 patients (64%) for whom intravenously administered propranolol did not prevent syncope during the tilt test (P < 0.015). The survival analysis with respect to the recurrence of syncope revealed a significant correlation between the results of the tilt test with intravenously administered propranolol and the efficacy of the long-term beta-blocker therapy (P < 0.003). There were no significant differences with respect to the predictive value of the tilt test with propranolol between the patients showing complete and partial propranolol efficacy (ns), while significant differences were observed between these two groups on one hand and the patients in whom intravenously administered propranolol was found ineffective on the other (P < 0.04 and P < 0.002, respectively).


CONCLUSIONS
Intravenous propranolol prevents tilt-induced syncope in a significant percentage of patients. The results of the tilt tests combined with the administration of propranolol predict the efficacy of a continuous propranolol treatment. Both complete and partial propranolol efficacy at tilt test can successfully identify those patients who will benefit from continuous beta blockade.
Gielerak
Grzegorz
G
Department of Internal Diseases and Cardiology, Military Medical Institute, Warsaw, Poland. gielarak@wim.mil.pl
Makowski
Karol
K
Cholewa
Marian
M
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D016016:Proportional Hazards Models; D011433:Propranolol / Q000008:administration & dosage*; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D019462:Syncope, Vasovagal / Q000503:physiopathology / Q000517:prevention & control*; D018667:Tilt-Table Test; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol